Brutalist Biotech

• GSK telegraphs 'very limited number' of job cuts amid R&D investment spree (11h)
• HHS terminates employees after Supreme Court allows reduction in force to proceed (12h)
• Sellas’ CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study (16h)
• Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M (16h)
• Hengrui’s GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push (17h)
• Acumen taps JCR’s blood-brain barrier tech for $555M Alzheimer’s deal (18h)
• China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies report (1d)
• Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials (1d)
• Research non-profit to acquire embattled Essa in Xoma Royalty-backed deal (1d)
• Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing (1d)

• Cancer drugmaker LaNova to sell to China’s Sino Biopharm (15h)
• Hengrui, Kailera say dual-acting obesity shot succeeds in China study (15h)
• Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug (16h)
• AstraZeneca blood pressure drug succeeds in late-stage trial (1d)
• Private equity firms back PCI Pharma in strategic bet on drug production (1d)
• FDA rejects Ultragenyx gene therapy over manufacturing concerns (1d)
• Takeda to seek approval of new kind of narcolepsy drug after study data (1d)
• From data to decisions: How pharma can move faster without sacrificing trust (1d)
• Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (4d)
• With Verona deal, Merck wagers on strength of lung drug’s patents (4d)

• BMS warns against ‘indiscriminate use’ of renegotiations as CMS plans next drug price talks (11h)
• About 2.5% of all drug patents cite government funding, new study finds (12h)
• GenBioPro loses bid to overturn West Virginia anti-abortion law (12h)
• Prasad overrode FDA vaccine reviewers on Moderna's Covid shot for young kids (12h)
• FDA questions the return of GSK's Blenrep in multiple myeloma ahead of adcomm (13h)
• Merck's partner LaNova Medicines is acquired for $951M by Sino Biopharmaceutical (15h)
• Labcorp drums up competition for health testing startups (15h)
• Otsuka buys immunology drugs; JCR, Acumen team up on Alzheimer’s program (16h)
• The Trump administration disbanded a federal newborn screening panel. Advocates now face a harder path (17h)
• Hengrui plans China filing for obesity shot following pivotal success (19h)

• Audrey Greenberg: Out to Change the World, From Housing to Healthcare (2h)
• AI-Focused Biotech Unicorns Face Chilly Market Where IPOs Aren’t Guaranteed (2h)
• 5 Women Biotech Leaders Bagging Billions in M&A Dollars (2h)
• Bonus Episode: Q1 2025 Job Market Update (16h)
• HHS Begins Formally Laying Off Employees (16h)
• Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25 (17h)
• FDA Commissioner Marty Makary Proposes Lowering Industry User Fees (18h)
• Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III (18h)
• Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions (1d)
• The Gap Between Administration’s Pro-Innovation Words and Policy (1d)

Bio IT World

• A Popular Alzheimer’s Biomarker Found at High Levels in Newborns (1h)
• Pharma Companies Finding Their Way with AI (1d)
• Trends from the Trenches: What a TV Scientist Knows About Teaching Science (6d)
• From Physics to Longevity: How Gero’s ProtoBind-Diff Tool Reads Nature’s Hidden Drug Library (1w)
• Population Genomics Projects Around the World Gaining Ground (1w)
• Virtual Cell Challenge Announces Prize for AI Models of Cellular Response (2w)
• Anne Wojcicki Buys Back 23andMe for $305M, Promises Data Security (2w)
• Real-Time Drug Monitoring: A New Era for Drug Discovery and Development (2w)
• UK Study Demonstrates Real-World Value of Genetic Testing for Drug Prescribing (3w)
• Follow the Money: ITM’s Gastroenteropancreatic Therapy, GRIN, Angelini Pharma Collaborates, More (3w)

• ViiV expands licensing deal for its HIV drug in low-income countries (9h)
• Federal judge reverses rule that would have removed medical debt from credit reports (11h)
• A troubled Sun Pharma plant fails yet another FDA inspection (14h)
• RFK Jr. gives vaccine skeptics plum HHS posts (15h)
• Kailera drug shows notable weight loss in China trial (16h)
• We’re reading about FDA user fees, rising GLP-1 use by children, and lots more (17h)
• The FDA approved another natural food dye (17h)
• HHS efficiency review blamed for delaying patient care at Indian Health Service (22h)
• A well-placed biotech investor says U.S. policies are straining life sciences startups (22h)
• The end of animal testing? Transitioning to models is promising — but no silver bullet (22h)

• Google Expands MedGemma Collection With Multimodal Health AI Models for Open Development (5d)
• Xaira Therapeutics Appoints Biotech Exec Behind Belharra and Ambys as President and COO to Scale AI-Driven Drug Discovery Platform (6d)
• NIH To End Funding for Animal-Only Studies, Backing Shift to New Approach Methodologies (6d)
• datma Launches Free Tool for Pharma to Assess Biomarker Coverage in Federated RWD (6d)
• AbbVie Acquires Capstan Therapeutics for $2.1B, Gaining In Vivo CAR-T Platform Targeting Autoimmune Diseases (2w)
• Chai Discovery Releases All-Atom Foundation Model for Zero-Shot Antibody Design with 16–20% Hit Rates (2w)
• Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome (2w)
• Arc Institute Opens Virtual Cell Challenge With $175K in AI Benchmarking Prizes (3w)
• SandboxAQ Releases Public Database Containing 5.2 Million Synthetic Protein-Ligand Structures (3w)
• DeepMind Introduces New AI Tool for Predicting Effects of Human DNA Variants (3w)

• Serial acquirer Concentra Biosciences on a buyout spree in 2025 (17h)
• Top biotech books of all time (1d)
• XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry? (4d)
• How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder (5d)
• Radiopharma’s new wave: Nuclidium and Actithera raise the stakes (5d)
• New hope for CIPN: Can emerging therapies ease chemotherapy’s nerve damage? (6d)
• The biggest biotech funding rounds in June 2025 (1w)
• Biotech in Vienna: a budding life science hub (1w)
• 14 biotech companies to know in the Boston area in 2025 (2w)
• Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms (2w)

• AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+ (7h)
• Global Neurodegeneration Proteomics Consortium Uncovers Biomarkers and Mechanisms (15h)
• Rapid Pathogen Detection in Low-Resource Settings Using Open-Source RT-LAMP Assay (18h)
• Feline Fever: Cell Therapy in Cats Sheds Clues on Long COVID (19h)
• $17.5B Deal Combines Waters with BD’s Biosciences and Diagnostics Business (1d)
• Recent NAM Guidelines Provide Much-Needed Step toward a More Productive Biotech Industry (1d)
• Elegen and Nutcracker Pilot Cell-Free Manufacturing Process for RNA-Based Personalized Cancer Therapeutics (1d)
• Catch a Fraudulent Scientist If You Can (1d)
• Consortium Aims to Deliver Fully-automated Robotics CGT Manufacturing Platform (1d)
• Novel Optogenetics Drug Discovery Screening Platform Identifies Antivirals (1d)

• How Love Helped Me Face Leukemia and Keep Living (9h)
• How Biomarker Testing Can Inform Metastatic Breast Cancer Care (10h)
• Coping With a Rare Cancer Diagnosis, Like GIST (11h)
• Refining Treatment Approaches and Advancements in High-Risk Melanoma (13h)
• Celebrating My Clean Bill of Health After Cancer (14h)
• Bria-IMT Improves Survival in Patients With Metastatic Breast Cancer (15h)
• Evaluation and Diagnosis of Multiple Myeloma (16h)
• Introduction and Overview of Multiple Myeloma (16h)
• How ADCs Are Redefining Chemotherapy in Breast Cancer Care (17h)
• Finding Freedom and Uncertainty in My Cancer Remission Pause (1d)

Contract Pharma*

• Zhaoke Ophthalmology, Fareva Sign Memorandum of Agreement (15h)
• IL Group Introduces Light Protect Pack (15h)
• Evestia Clinical Merges with Atlantic Research Group (15h)
• 365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea (16h)
• Antares Vision Group, LedgerDomain Partner to Streamline Supply Chain Security (17h)
• MilliporeSigma Introduces Automated Assay Workstation (17h)
• AATec Medical & Northway Biotech Develop ATL-105 (17h)
• Gil Roth - The Medicine Maker (1d)
• Uniquity Bio Appoints Will Kane President and CEO (1d)
• PCI Pharma Services Receives Strategic Investment from Bain Capital, Kohlberg and Mubadala (1d)

• NHS England secures access to new cystic fibrosis treatment ALYFTREK (18h)
• MHRA approves first oral treatment for hereditary angioedema attacks (18h)
• Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer (1d)
• Imperial study reveals DNA structure that could reverse ovarian cancer resistance (1d)
• Government to adopt EU standards for high-risk diagnostic devices (5d)
• Osivax publishes phase 2a results supporting dual flu vaccine approach (5d)
• BiomX phage therapy shows potent effect in cystic fibrosis trial (7d)
• Actithera closes $75.5m Series A to advance radioligand therapy platform (7d)
• VarmX secures US approval to begin phase 3 trial of urgent surgery treatment (1w)
• Clinical Researcher of the Year – The Americas (1w)

• Report: Majority of Medicare Advantage Markets Lack Competition (8h)
• How Allina Health Is Modernizing Its Supply Chain Strategy (10h)
• Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study (12h)
• No More Band-Aids: Hiring Isn’t the Answer to Burnout (16h)
• Generation Generative: What Healthcare Marketers Need To Know About Generative AI (16h)
• The Definitive Guide to Medical Billing Outsourcing: 5 Top Companies (17h)
• Why Hospitals Are Losing the Financial Tug-of-War With Payers (1d)
• New Bipartisan Bill from Rep. Carter Aims to Crack Down on PBMs (1d)
• Bayer’s Blockbuster Hopeful Kerendia Expands its FDA Approval to Type of Heart Failure (1d)
• Behavioral Health Has A Data Problem. Health Plans Are Sitting On The Solution (1d)

• Waters to acquire BD flow cytometry business in a deal valued at $17.5 billion (11h)
• AI tool uses team approach to solve quantum chemistry problems (16h)
• ‘We have committed ourselves to this toxicity’ (1d)
• Team USA brings home gold at 57th International Chemistry Olympiad (1d)
• Chemistry in Pictures: That’s no moon (1d)
• US invests in rare earth firm MP Materials (4d)
• Protein sequences decoded from extremely old mammal teeth (4d)
• Atom-swapped morphine may help create safer painkillers (4d)
• Chemistry merit badge gets a new formula (4d)
• Gold Hydrogen raises funds for geological hydrogen (4d)

The Pharma Letter*

• How tech transfer timelines can make or break an oral drug launch (12h)
• ICER assesses tolebrutinib’s worth in SPMS (13h)
• Hengrui and Kailera ready to file for approval of obesity candidate on positive Phase III trial (15h)
• Russia to begin commercial production of new anticancer vaccine (15h)
• ViiV's HIV portfolio delivering on different fronts (16h)
• Hidden cost of 340B: a multi-billion-dollar burden on taxpayers and Medicaid (16h)
• MHRA approves Ekterly to treat HAE (16h)
• New RayzeBio hub promises to deliver radiopharmaceutical therapies in three days (17h)
• Tract Bio adds CMO and board members as stem cell pipeline advances (17h)
• Otsuka bets on Cantargia in deal worth up to $613 million (18h)

• Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral (11h)
• Medina on Patient Selection for Lifileucel in Melanoma (12h)
• Targeted Brain Radiation Yields Promising Outcomes in SCLC Brain Metastases (13h)
• Stereotactic Radiation: New Standard for Brain Metastases (14h)
• Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial (15h)
• FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy (16h)
• PROGRxN-BCa AI Model Shows Broad Accuracy in NMIBC Prediction (16h)
• Tabelecleucel Advances in EBV+ PTLD With Phase 3 Trial and FDA Resubmission (17h)
• Dr Weiss Reviews Key Melanoma Updates From ASCO 2025 (17h)
• Recent Clinical Advances: Key Trial Data in First-Line mTNBC (17h)

• Convatec sees risk of Medicare proposal hitting patients (18h)
• Coloplast welcomes US' extensive cost-saving on wound care (20h)
• Coloplast and rivals fall on stock exchange: Medicare to limit skin and wound care spending (21h)
• EU countries support robust response to Trump if tariff deal fails (22h)
• China biotech’s stunning advance is changing the world’s drug pipeline (22h)
• Tylenol-maker Kenvue appoints interim CEO (1d)
• US Administration's price plans for big pharma will lead to fighting (1d)
• Leo Pharma signs multi-million-euro deal with Boehringer Ingelheim: Acquires rights to psoriasis drug (1d)
• EU considers new counter-tariffs to ensure fair deal with the US (1d)
• AstraZeneca rewarded on the stock exchange after strong data with blood pressure drug (1d)

• Dual Antibody Conjugates For Twice the Excitement (8h)
• Sulfonate Esters in Drug Substances: Real Problem or Not? (1d)
• Senolytic Update (5d)
• Hexanitrogen Energies (6d)
• Thinking About Covalent Drug Reactivity (1w)
• Tell the Bot to Tell the Bot About the Bot (1w)
• The Fourth Of July, 2025 (2w)
• New Assays Are Always Welcome (2w)
• Down In the Reaction Details (2w)
• The "Healthy Vaccinee" Effect (3w)

• Hengrui to file obesity shot in China after phase 3 win (18h)
• LEO bulks up with deal for Boehringer skin drug (18h)
• Gilead's twice-yearly HIV PrEP set for wider rollout (20h)
• UK Biobank charts success of NHS imaging project (21h)
• New cystic fibrosis triple from Vertex backed for NHS use (21h)
• UK project addresses capacity issue in CGT manufacturing (1d)
• Takeda's narcolepsy programme gets back on track (1d)
• AZ prepares to file blood pressure drug after trial win (1d)
• Bayer gets sought-after heart failure use for Kerendia (1d)
• Paper gives hint of Apple's thinking on AI and health (1d)

• SLC7A11 inhibitors could remove skin cancer’s protective armour (14h)
• FUJIFILM’s biliary tract cancer drug granted FDA orphan status (17h)
• Mezagitamab and the future of ITP treatment (19h)
• JCR and Alexion deal boosts AAV-based gene therapy (20h)
• EU go-ahead for nasopharyngeal carcinoma drug (21h)
• US company hopes to transform access to advanced biologics (22h)
• Industry insights from Q2 2025 events (1d)
• New DDW Highlights podcast: 14 July 2025 (1d)
• DDW Highlights: 14 July 2025 (1d)
• Atsena expedites gene therapy for X-linked retinoschisis (1d)

Google News Biotech

• Danaher and Shanghai biotech company announce strategic partnership - China Daily (47m)
• 4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis - Yahoo (1h)
• AI-Focused Biotech Unicorns Face Chilly Market Where IPOs Aren’t Guaranteed - BioSpace (2h)
• 5 Women Biotech Leaders Bagging Billions in M&A Dollars - BioSpace (2h)
• Innovative Pharmaceutical Biotech Announces Trading Halt Amid Pending Inside Information - TipRanks (3h)
• Queensland biotech Eclipse Ingredients banks $7 million for protein production - Startup Daily (6h)
• Cargill Opens BioTech Center for Sustainable Manufacturing - Twin Cities Business (7h)
• Innovative Pharmaceutical Biotech Announces New Share Issuance - TipRanks (7h)
• NKarta chief Paul Hastings discusses thriving in biotech amid political turmoil - BioProcess International (8h)
• Buffalo Trace, Meridian Biotech Team to Turn Stillage into High‑Value Alternative Proteins - Smiley Pete Publishing (8h)